ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2229

Alleviation Of Collagen-Induced Arthritis By Multifunctional Nanoparticle Containing Methotrexate

You-Jung Ha1, Sun-Mi Lee2, Ji-Hee Lim1, Hyung-Joon Kim2, Sang-Won Lee3, Soo Kon Lee4, Kyung-Hwa Yoo2 and Yong-Beom Park5, 1Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 2Nanomedical Graduate Program, Department of Physics, Yonsei University, Seoul, South Korea, 3Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea, 4Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 5Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: methotrexate (MTX), nanomedicine and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Methotrexate (MTX) is the most widely used disease-modifying anti-rheumatic drugs for the treatment of rheumatoid arthritis (RA). Despite of its efficacy, the continuous use of MTX is often accompanied by several adverse effects, especially in high-dosage MTX. We developed the multifunctional nanoparticle (MNP; Poly(DL-lactic-co-glycolic acid)-Au half-shell coated nanoparticles) containing 0.2mg/kg of MTX. Upon near-infrared (NIR) irradiation, these MNP can enhance the drug release and generate heat by Au half-shells. This study aimed to investigate the therapeutic efficacy of MNP containing MTX in a murine model of arthritis.

Methods: Collagen-induced arthritis (CIA) was induced in male DBA/1J mice by immunization with bovine type II collagen. Thirty CIA mice were divided into 6 groups (untreated, conventional MTX (35 mg/kg x 8 times intraperitoneal), MTX 0.2mg/kg once intravenous (IV), MTX-unloaded MNP IV with NIR, MTX-loaded MNP IV, and MTX-loaded MNP IV with NIR). The clinical scores and hind paw thickness were evaluated. Histopathologic assessment of joint sections was performed. The serum levels of pro-inflammatory cytokines were measured by enzyme-linked immunosorbent assay.

Results: Treatment of MTX-loaded MNP with NIR significantly alleviated the severity of the arthritis, based on the reduced hind paw swelling and clinical scores, compared with untreated CIA mice. The treatment efficacy of MTX-loaded MNP with NIR group was comparable to that of conventional MTX-treated group. However, arthritis was not ameliorated in the mice treated with MTX 0.2mg/kg once or MTX-unloaded MNP with NIR. Treatment of MTX-loaded MNP without NIR showed partial treatment response only in an early treatment period. Histopathologic analyses and serum pro-inflammatory cytokines showed the similar pattern.

Conclusion: Treatment efficacy of MTX-loaded MNP with NIR was similar with conventional treatment in a much smaller dosage of MTX (about 1/1000 of MTX). Our results showed that this novel drug delivery system using MNP can be a new therapeutic tool for treatment of RA.


Disclosure:

Y. J. Ha,
None;

S. M. Lee,
None;

J. H. Lim,
None;

H. J. Kim,
None;

S. W. Lee,
None;

S. K. Lee,
None;

K. H. Yoo,
None;

Y. B. Park,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/alleviation-of-collagen-induced-arthritis-by-multifunctional-nanoparticle-containing-methotrexate/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology